Bristol-Myers Squibb Company
Financial Performance
Bristol-Myers Squibb Revenue & Financials
Revenue
$48.2B (FY2025)
Market Cap
$127.5B
Net Income
$7.1B
Employees
32,500
What is Bristol-Myers Squibb's revenue?
Bristol-Myers Squibb had $48.2B in revenue for fiscal year 2025, down 0.2% from 2024. Net income was $7.1B.
- Latest revenue
- $48.2B (FY2025)
- Year-over-year
- -0.2%
- Growth rate (CAGR)
- 10.6% over 9 years
- Peak revenue
- $48.3B (FY2024)
- Years of data
- 10
- Employees
- 32,500
- How much profit does Bristol-Myers Squibb make?
- Bristol-Myers Squibb reported net income of $7.1B for fiscal year 2025. sec.gov
- How many employees does Bristol-Myers Squibb have?
- Bristol-Myers Squibb has about 32,500 employees.
Financial Analysis
Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion. Bristol Myers Squibb is a dominant force in global biopharmaceuticals, sustaining a massive market valuation that regularly exceeds $100 billion.
Revenue Trend Analysis
YoY Change
-0.2%
9-Year CAGR
+10.6%
Peak Year
2024
Trend
Mostly Growing
Bristol-Myers Squibb Company has 10 full fiscal year figures on this page, compounding at +10.6% annually over 9 years. The most recent year saw a 0.2% decline versus the prior year. Annual revenue peaked in fiscal year 2024 at $48.3B. Of 9 comparable year-over-year steps, 6 showed growth and 3 showed a decline.
Annual revenue history
| Fiscal Year | Revenue | Net Income | YoY Change | Source |
|---|---|---|---|---|
| FY2025 | $48.2B | $7.1B | -0.2% | sec.gov Total revenues $48.194B, down 0.2%; Growth Portfolio up 17% to $26.4B. Net earnings attributable to BMS $7.054B (GAAP EPS $3.46). |
| FY2024 | $48.3B | -$8.9B | +7.3% | bms.com Revenue up 7% to $48.3B; GAAP net loss of $8.948B driven by the acquired in-process R&D charge for Karuna. |
| FY2023 | $45B | $8B | -2.5% | data.sec.gov Revenue down 2.5% as generic lenalidomide cut Revlimid sales; net earnings $8.025B. |
| FY2022 | $46.2B | $6.3B | -0.5% | stockanalysis.com Revenue down 0.5%; first year of volume-limited Revlimid generics in the U.S. Net earnings $6.327B. |
| FY2021 | $46.4B | $7B | +9.1% | stockanalysis.com Revenue up 9% in the first full year after the Celgene integration; Revlimid peaked at $12.8B. Net earnings $6.994B. |
| FY2020 | $42.5B | -$9B | +62.6% | investors.bms.com First full year including Celgene. GAAP net loss (EPS -$3.99) after an $11.4B in-process R&D charge for MyoKardia. |
| FY2019 | $26.1B | $3.4B | +15.9% | investors.bms.com Revenue up 16%; includes Celgene from November 20, 2019. Net earnings attributable to BMS $3.439B. |
| FY2018 | $22.6B | $4.9B | +8.6% | investors.bms.com Revenue up 9% on Opdivo and Eliquis demand. Net earnings attributable to BMS $4.920B. |
| FY2017 | $20.8B | $1B | +6.9% | s21.q4cdn.com Revenue up 7% to $20.8B; net earnings cut to about $1.0B by a U.S. tax reform charge. |
| FY2016 | $19.4B | $4.5B | — | investors.bms.com Revenue up 17% from $16.56B in 2015 on Opdivo and Eliquis growth. Net earnings attributable to BMS $4.457B. |
Click any row to see year details.
Bristol-Myers Squibb Company balance sheet and cash flow
Balance-sheet figures are as of each fiscal year end; cash-flow figures cover the fiscal year. Taken from the company's annual report on Form 10-K, linked on each row. Free cash flow here is operating cash flow less capital expenditures, calculated by CorpDigest.
| Fiscal Year | Operating cash flow | Capital expenditures | Total assets | Total liabilities | Shareholders' equity | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $14.2B | $1.3B | $90B | $71.5B | $18.5B | $12.8B | Form 10-K |
| FY2024ended Dec 31, 2024 | $15.2B | $1.2B | $92.6B | $76.2B | $16.3B | $13.9B | Form 10-K |
| FY2023ended Dec 31, 2023 | $13.9B | $1.2B | $95.2B | $65.7B | $29.4B | $12.7B | Form 10-K |
| FY2022ended Dec 31, 2022 | $13.1B | $1.1B | $96.8B | $65.7B | $31.1B | $11.9B | Form 10-K |
| FY2021ended Dec 31, 2021 | $16.2B | $973M | $109.3B | $73.3B | $35.9B | $15.2B | Form 10-K |
| FY2020ended Dec 31, 2020 | $14.1B | $753M | $118.5B | $80.6B | $37.8B | $13.3B | Form 10-K |
| FY2019ended Dec 31, 2019 | $8.2B | $836M | $129.9B | $78.2B | $51.6B | $7.4B | Form 10-K |
| FY2018ended Dec 31, 2018 | $7.1B | $951M | $35B | $20.9B | $14B | $6.1B | Form 10-K |
| FY2017ended Dec 31, 2017 | $5.3B | $1.1B | $33.6B | $21.7B | $11.7B | $4.2B | Form 10-K |
| FY2016ended Dec 31, 2016 | $3.1B | $1.2B | $33.7B | $17.4B | $16.2B | $1.8B | Form 10-K |
Related Companies
Compare Bristol-Myers Squibb Company Revenue With Competitors
Keep researching Bristol-Myers Squibb
Bristol-Myers Squibb Revenue and Financial FAQ
What was Bristol Myers Squibb's revenue in 2025?
$48.194 billion, down 0.2 percent from $48.300 billion in 2024. The Growth Portfolio rose 17 percent to $26.4 billion while the Legacy Portfolio fell to $21.8 billion.
Is Bristol Myers Squibb profitable?
Yes in 2025: net earnings attributable to BMS were $7.054 billion, or $3.46 per share on a GAAP basis and $6.15 on a non-GAAP basis. It reported a net loss of $8.948 billion in 2024.
Why did BMS report losses in 2020 and 2024?
Both came from acquired in-process R&D charges, not weaker sales. The $11.4 billion MyoKardia charge produced a 2020 net loss of about $9.0 billion, and the Karuna charge produced the $8.9 billion loss in 2024.
What is Bristol Myers Squibb's 2026 guidance?
On July 30, 2026 BMS raised 2026 revenue guidance to about $49.0 to $50.0 billion, from $46.0 to $47.5 billion, and non-GAAP EPS guidance to $6.75 to $7.00. Second-quarter revenue rose 6 percent to $12.97 billion.
Which BMS drugs generate the most revenue?
In 2025: Eliquis $14.4 billion, Opdivo $10.0 billion, Orencia $3.7 billion, Revlimid $3.0 billion, Yervoy $2.9 billion, Pomalyst/Imnovid $2.7 billion and Reblozyl $2.3 billion.
How much has generic competition cut Revlimid sales?
Revlimid peaked at $12.8 billion in 2021 and fell to $3.0 billion in 2025 after volume-limited generic lenalidomide entered the U.S. market in 2022.
How much debt does Bristol Myers Squibb have?
Total debt was about $47.2 billion at the end of 2025, down from $51.2 billion a year earlier, against about $11.1 billion of cash and investments. Free cash flow was about $12.8 billion in 2025.
What dividend does Bristol Myers Squibb pay?
In February 2026 BMS raised its quarterly dividend to $0.63 per share, its 17th consecutive annual increase.
What is Bristol Myers Squibb's market cap?
About $127.5 billion at the September 30, 2026 close, when the shares ended at $62.40.
Is Bristol-Myers Squibb profitable?
Yes, it is massively profitable, generating tens of billions in free cash flow primarily from a few key blockbuster drugs, though it faces severe financial pressure as those patents expire.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Bristol-Myers Squibb Revenue & Financials." CorpDigest, https://corpdigest.com/company/bristol-myers-squibb/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Bristol-Myers Squibb reported $48.2B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/bristol-myers-squibb/financials" target="_blank" rel="noopener">CorpDigest — Bristol-Myers Squibb financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore Bristol-Myers Squibb
Core profile pages, founders and related research hubs for this company.